{"id":"NCT00422383","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)","officialTitle":"A Randomized, Double-blind Study to Evaluate the Effect of Various Re-treatment Regimens of MabThera in Combination With Methotrexate on Treatment Response in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2007-01-17","resultsPosted":"2015-05-04","lastUpdate":"2015-05-04"},"enrollment":378,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]},{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]},{"type":"DRUG","name":"rituximab [MabThera/Rituxan]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the efficacy and safety of various treatment and retreatment regimens of MabThera. All patients will receive concomitant methotrexate, 10-25mg once weekly either orally or parenterally. The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.","primaryOutcome":{"measure":"Percentage of Participants With a Response as Determined by American College of Rheumatology (ACR) 20% Improvement (ACR20)","timeFrame":"Week 48","effectByArm":[{"arm":"Rituximab Low Dose + Methotrexate","deltaMin":64.2,"sd":null},{"arm":"Rituximab Escalated Dose + Methotrexate","deltaMin":63.9,"sd":null},{"arm":"Rituximab High Dose + Methotrexate","deltaMin":72,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8156"},{"comp":"OG000 vs OG002","p":"0.2419"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":91,"countries":["Australia","Belgium","Brazil","Canada","China","Finland","France","Germany","Hungary","Italy","Netherlands","New Zealand","Slovakia","South Africa","Spain","Taiwan","Thailand","United Kingdom"]},"refs":{"pmids":["20463186"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":134},"commonTop":["Infusion related reaction","Rheumatoid arthritis","Upper respiratory tract infection","Nasopharyngitis","Urinary tract infection"]}}